Diloxanide furoate

Diloxanide furoate

Clinical data
Trade names	Furamide
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	No available data
Routes of administration	by mouth
ATC code	P01AC01 (WHO)
Legal status
Legal status	CA: Not approved US: Not approved
Pharmacokinetic data
Bioavailability	90% (diloxanide)
Metabolism	Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation
Biological half-life	3 hours
Excretion	Kidney (90%), fecal (10%)
Identifiers
IUPAC name 4-[(Dichloroacetyl)(methyl)amino]phenyl furan-2-carboxylate
CAS Number	3736-81-0 N
PubChem CID	19529
DrugBank	DB08792 Y
ChemSpider	18400 Y
KEGG	D02480 Y
ChEMBL	CHEMBL1334860 N
ECHA InfoCard	100.021.008
Chemical and physical data
Formula	C14H11Cl2NO4
Molar mass	328.147 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(Oc1ccc(N(C(=O)C(Cl)Cl)C)cc1)c2occc2
InChI InChI=1S/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3 Y Key:BDYYDXJSHYEDGB-UHFFFAOYSA-N Y
NY (what is this?)

Diloxanide is a medication used to treat amoeba infections. It is a second line treatment after paromomycin when no symptoms are present in places where infections are not common. For people who are symptomatic, it is used after treatment with metronidazole or tinidazole. It is taken by mouth.

Diloxanide generally has mild side effects. Side effects may include flatulence, vomiting, and itchiness. During pregnancy it is recommended that it be taken after the first trimester. It is a luminal amebicide meaning that it only works on infections within the intestines.

Diloxanide came into medical use in 1956. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not commercially available in much of the developed world as of 2012.

Dloxanide furoate works only in the digestive tract and is a lumenal amebicide. It is considered second line treatment for infection with amoebas when no symptoms are present but the person is passing cysts, in places where infections are not common.Paromomycin is considered the first line treatment for these cases.

For people who are symptomatic, it is used after treatment with ambecides that can penetrate tissue, like metronidazole or tinidazole. Diloxanide is considered second-line, while paromomycin is considered first line for this use as well.

Side effects include flatulence, itchiness, and hives. In general, the use of diloxanide is well tolerated with minimal toxicity. Although there is no clear risk of harm when used during pregnancy, diloxanide should be avoided in the first trimester if possible.